Lenalidomide subcutaneous infusion (Starton Therapeutics)

来那度胺皮下输注 (Starton Therapeutics)

Report date: 2026/02/27 20:01:47

Base Information

Drug NameLenalidomide subcutaneous infusion (Starton Therapeutics)
Drug Alias NameSTAR LLD programmeCMIO-LLDSTAR-LLD-SC
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCereblon modulatorsDNA-binding protein Ikaros degradersZinc finger protein Aiolos degraders +[4] 
TargetsCereblonDNA-binding protein IkarosZinc finger protein Aiolos +[4] 
Therapy Area/IndicationsMultiple MyelomaLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesStarton Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesStarton Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A